整合临床与影像生物标志物以应对帕金森病
Merging Clinical and Imaging Biomarkers to Tackle Parkinson's Disease.
作者信息
Picillo Marina, Barone Paolo, Pellecchia Maria Teresa
机构信息
Neuroscience Section Department of Medicine and Surgery Center for Neurodegenerative Diseases (CMAND) University of Salerno Salerno Italy.
出版信息
Mov Disord Clin Pract. 2017 Aug 21;4(5):652-662. doi: 10.1002/mdc3.12521. eCollection 2017 Sep-Oct.
BACKGROUND
In Parkinson's disease, biomarkers represent tools that are potentially suitable for either clinical or research settings and are useful in predicting onset, confirming diagnosis, detecting progression, and evaluating response to potential disease-modifying treatments. The range of available biomarkers in Parkinson's disease is fast expanding and includes an increasing amount of laboratory, clinical, and imaging data. Indeed, the latter 2 represent the cornerstones of the diagnostic criteria for Parkinson's disease recently proposed by the International Parkinson and Movement Disorders Society Task Force on the definition of Parkinson's disease.
METHODS AND RESULTS
In this review, we describe current knowledge and emerging findings on clinical (with emphasis on nonmotor symptoms) and imaging biomarkers for Parkinson's disease, with a focus on prodromal, diagnostic, and middle/advanced phases.
CONCLUSION
An increasing body of evidence suggests that merging clinical and imaging biomarkers through disease stages may be the best, fastest track to tackle Parkinson's disease.
背景
在帕金森病中，生物标志物是可能适用于临床或研究环境的工具，有助于预测发病、确诊、检测疾病进展以及评估对潜在疾病修饰治疗的反应。帕金森病可用生物标志物的范围正在迅速扩大，包括越来越多的实验室、临床和影像数据。事实上，后两者是国际帕金森病和运动障碍协会帕金森病定义特别工作组最近提出的帕金森病诊断标准的基石。
方法与结果
在本综述中，我们描述了帕金森病临床（重点是非运动症状）和影像生物标志物的现有知识和新发现，重点关注前驱期、诊断期和中/晚期。
结论
越来越多的证据表明，通过疾病阶段整合临床和影像生物标志物可能是应对帕金森病的最佳、最快途径。
Zotero 插件